Sensei Biotherapeutics, Inc. has decided to discontinue development of solnerstotug and explore strategic alternatives to maximize shareholder value. The company will implement workforce reductions to preserve cash and maintain a small team to manage the wind-down of activities. Sensei’s CEO stated that solnerstotug showed promise, but future funding needs led to this decision. The company will not provide updates on the strategic process unless a transaction is approved. Sensei is a clinical-stage biotech company focused on developing cancer therapeutics and is currently pursuing strategic alternatives.

Read more at GlobeNewswire: Sensei Biotherapeutics Announces Initiation of Strategic